Outcome: One publication has been published and one patent is pending
This project advances the field of nanomedicine by introducing a simpler, more effective ligand attachment method compared to conventional drug delivery functionalization techniques. Key breakthroughs include:
✅ Simplicity and Speed: Unlike traditional multi-step chemical conjugation methods, this technique enables ligand attachment through simple mixing, reducing processing time and cost.
✅ Enhanced Drug Carrier Versatility: The method is adaptable to different clinically approved drug carriers, including PEGylated liposomes (Doxil®) and polymeric micelles (Genexol-PM), expanding its potential applications.
✅ Personalized Therapy Potential: The “mix and match” strategy allows for the attachment of multiple targeting ligands, enabling more precise and adaptable cancer treatments.
These results position the one-step activation method as a game-changing approach in targeted drug delivery, facilitating the clinical translation of personalized nanomedicine.
Key Requirements for Further Uptake and Success
To move from proof of concept to clinical application, several key steps must be addressed:
Further Research & Preclinical Validation: Additional in vivo studies are required to confirm the therapeutic benefits, stability, and biodistribution of the functionalized drug carriers.
Regulatory Compliance & Standardization: Engagement with regulatory agencies (EMA, FDA) will be essential to define approval pathways for integrating this method into existing drug formulations.
IPR Strategy & Commercialization: Patents are being prepared to protect the intellectual property, and discussions with pharmaceutical companies for licensing opportunities are underway.
Access to Markets & Industry Partnerships: Collaboration with biotech and pharmaceutical companies will be key to scaling production and ensuring market adoption.
Expected Impact
By applying this one-step activation process, existing clinically approved drug carriers can be rapidly transformed into targeted drug delivery systems without altering their original structure. The anticipated benefits include:
Higher drug uptake by cancer cells, improving treatment efficacy.
Reduced systemic toxicity, leading to fewer side effects for patients.
Increased accessibility and affordability, as the method simplifies production and lowers costs.
The success of this project could accelerate the clinical translation of targeted therapies by simplifying the functionalization of nanocarriers, thus improving their efficiency and applicability in modern oncology. Beyond cancer treatment, this technology could potentially be extended to other diseases requiring targeted drug delivery, such as neurodegenerative disorders or inflammatory diseases.
Outcomes of the Action
By the end of the project, the following key outcomes will be achieved:
A validated one-step activation method that successfully enhances the targeting efficiency of clinically approved drug carriers.
Demonstration of improved cellular uptake and drug delivery in in vitro cancer models.
Establishment of an IP and commercialization strategy, including discussions with potential industrial partners for further development.
Generation of data supporting future preclinical and clinical translation, paving the way for the next phase of development.
This ERC-supported innovation has the potential to revolutionize targeted drug delivery, ultimately leading to safer, more effective cancer treatments and paving the way for future applications in precision medicine.
